Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin

Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin

Interferon (IFN) and ribavirin (RBV) combination therapy was previously the standard of care for treatment of hepatitis C virus (HCV) genotype 2 infection. But, it often induced hemolytic anemia. In 2014, sofosbuvir (SOF) was approved for the treatment of chronic HCV genotype 2 in Japan. SOF/RBV the...

Full description

Saved in:
Bibliographic Details
Main Authors: Hirokazu Suii, Itaru Ozeki, Ryoji Tatsumi, Masakatsu Yamaguchi, Mutsuumi Kimura, Tomohiro Arakawa, Tomoaki Nakajima, Yasuaki Kuwata, Takumi Ohmura, Shuhei Hige, Yoshiyasu Karino, Joji Toyota
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Case Reports in Hepatology
Online Access:http://dx.doi.org/10.1155/2017/8793895
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items